Evicenter
Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer
Manufacturer
Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP
Prescribing information
Enhertu (opens in a new tab)
Questions
30
Last updated

All questions

Guidelines: Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer

1 question · 1 source

Guidelines

What is the NCCN recommendation for Enhertu in HR-positive HER2-low breast cancer?

Note: NCCN Guidelines for Breast Cancer V.4.2026, accessed by the manufacturer June 12, 2026, as quoted on the Enhertu HCP site captured November 13, 2026. A later NCCN version may state the recommendation differently.